Positive topline results from the Phase III HERCULES study with caplacizumab

October 2, 2017 ABLYNX "announced positive topline results from the Phase III HERCULES study with caplacizumab, the Company's anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)." View the full article.

July 26, 2017: Ablynx announced "that the Food and Drug Administration (FDA) has granted Fast Track designation for caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)." SOURCE: http://www.empr.com/drugs-in-the-pipeline/caplacizumab-attp-autoimmune-b....View the full article.